Lv12
20 积分 2024-06-22 加入
KRAS-G12D inhibitor HRS-4642 plus chemotherapy in advanced KRASG12D-mutant pancreatic cancer: a phase 1b/2 trial
12小时前
待确认
Concurrent genetic and non-genetic resistance mechanisms to KRAS inhibition in colorectal cancer
1天前
已完结
Deciphering KRAS inhibitor resistance
1天前
已完结
Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα
28天前
已完结
Mitomycin C vs. Bacillus Calmette-Guerin for treatment of intermediate-risk nonmuscle invasive bladder cancer patients-A comparative analysis from a single center
1个月前
已完结
Comparative Effectiveness of Bacillus Calmette-Guérin and Sequential Intravesical Gemcitabine and Docetaxel for Treatment-naïve Intermediate-risk Non-muscle-invasive Bladder Cancer
1个月前
已完结
Efficacy and Safety of Mitomycin Gel (UGN-101) as an Adjuvant Therapy After Complete Endoscopic Management of Upper Tract Urothelial Carcinoma
1个月前
已完结
RAS-ing the bar in the treatment of KRAS-mutant cholangiocarcinoma
1个月前
已完结
Diverging gain-of-function mechanisms of two novel KRAS mutations associated with Noonan and cardio-facio-cutaneous syndromes
1个月前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
1个月前
已完结
皖公网安备34019202002308
